Novel Endpoints for Heart Failure Clinical Trials

被引：6
作者：
Hamo C.E. [1 ]
Gheorghiade M. [2 ]
Butler J. [1 ]
机构：
[1] Department of Medicine, Division of Cardiology, Stony Brook University, T-16, Room 080, Stony Brook, 11794, NY
[2] Center for Cardiovascular Innovation, Feinberg School of Medicine, Northwestern University, Chicago, IL
来源：
Current Heart Failure Reports | 2017年 / 14卷 / 4期
关键词：
Clinical trial; Endpoint; Functional status; Heart failure; Quality of life;
D O I：
10.1007/s11897-017-0334-z
中图分类号：
学科分类号：
摘要：
Purpose of Review: With the growing prevalence of heart failure, there is a particular need to develop new pharmacologic treatments that can improve outcomes. While there are several approved therapies for heart failure with reduced ejection fraction, there is currently no approved agent for those with preserved ejection fraction. The current review aimed to explore the utility of alternate endpoints to mortality and hospitalization. Recent Findings: There is increased interest in the use of alternative endpoints such as functional status and quality of life for heart failure drug development to focus on patients feeling better in addition to improving outcomes. This should ideally be measured using objective as well as subjective parameters. Summary: While mortality and hospitalization remain important endpoints for clinical trials in heart failure, other more patient-centered outcomes are attractive alternatives yet how to best incorporate these in a trial setting remains to be elucidated. © 2017, Springer Science+Business Media, LLC.
引用
收藏
页码：210 / 216
页数：6
相关论文
共 53 条
[1]  
Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., Et al., 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 128, 16, pp. 1810-1852, (2013)
[2]  
Jencks S.F., Williams M.V., Coleman E.A., Rehospitalizations among patients in the Medicare fee-for-service program, N Engl J Med, 360, 14, pp. 1418-1428, (2009)
[3]  
Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., Et al., Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry, J Am Coll Cardiol, 50, 8, pp. 768-777, (2007)
[4]  
Yancy C.W., Lopatin M., Stevenson L.W., De Marco T., Fonarow G.C., Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database, J Am Coll Cardiol, 47, 1, pp. 76-84, (2006)
[5]  
Steinberg B.A., Zhao X., Heidenreich P.A., Peterson E.D., Bhatt D.L., Cannon C.P., Et al., Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes, Circulation, 126, 1, pp. 65-75, (2012)
[6]  
Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 3, pp. 251-259, (2006)
[7]  
Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Et al., Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, 3, pp. 260-269, (2006)
[8]  
Holland D.J., Kumbhani D.J., Ahmed S.H., Marwick T.H., Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis, J Am Coll Cardiol, 57, 16, pp. 1676-1686, (2011)
[9]  
Agarwal V., Briasoulis A., Messerli F.H., Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction, Heart Fail Rev, 18, pp. 429-437, (2013)
[10]  
Felker G.M., Maisel A.S., A global rank end point for clinical trials in acute heart failure, Circulation Heart failure, 3, 5, pp. 643-646, (2010)
123456